$ARGX News

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today

Wedbush Reiterates Outperform on argenx, Maintains $1150 Price Target

BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

argenx to Present at Upcoming Investor Conferences

Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1250

A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.

argenx (ENXTBR:ARGX) Stock Looks Rich Despite Its 210% Five Year Run

argenx (ENXTBR:ARGX) Just Gave Investors Something To Think About

Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition

argenx Completes Acquisition of Forte Biosciences, Inc.

UBS Just Upgraded Argenx Stock. Here's Why.

UBS Upgrades argenx to Buy, Raises Price Target to $1400

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story

Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1415

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis - Slideshow

ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up

Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says

Truist Securities Maintains Buy on argenx, Raises Price Target to $1095